

Curriculum Vitae et Studiorum- Silvestro Conticello

ORCID: 0000-0002-4244-1846

Scopus Author ID: 7003531993

Web of Science Researcher ID: G-9113-2011

Google Scholar ID: jxGJZA4AAAAJ

Website: <http://www.ispo.toscana.it/crl/oncogenesi>

biographical sketch

I started in Catania (Italy) where -after training as a medical doctor- moved to basic research with a PhD in biochemistry. My interest in gene diversification began at the Weizmann Institute (Israel), as a postdoc with Mike Fainzilber. There, I set up one of the first projects to analyse the diversity and the evolution of conotoxins, a large group of neuroactive molecules from the venoms of Conus snails. My fascination with genetic hypervariability and its role in the evolution of somatic cells brought me to the lab of Michael Neuberger at the MRC-LMB in Cambridge (UK) to work on the molecular mechanisms of antibody diversification. The following years were an exciting ride between bench and in silico work: from the evolutionary and structural origins of the AID/APOBECs -a family of DNA/RNA editors- to their targeting and the characterisation of the pathway that HIV uses to counteract the APOBEC3s -a branch of the AID/APOBECs active against viruses. Since 2007 I lead a lab in Florence at the ISPRO, and I am a researcher of the Institute of Clinical Physiology (CNR, Pisa). The research of my lab currently focuses on three main areas: the role of the AID/APOBECs in the evolution of cancer and as antiviral agents (e.g., against SARS-CoV-2); genome editing as a tool for cancer research and therapy; the use of third generation sequencing (Oxford Nanopore) to quantify and analyse circulating tumour DNA from liquid biopsy.

Positions

05/2022 – 03/2025 Responsabile della URT dell'IFC presso l'ISPRO, Firenze

09/2019 – 03/2025 Primo Ricercatore, Secondo livello, CNR IFC, Pisa

16/1/2018 - 2025 Group Leader of the "Molecular Mechanisms of Oncogenesis" Unit at the Core Research Laboratory - Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Firenze, Italy




- 7/2007 - 15/1/2018 Group Leader of the "Molecular Mechanisms of Oncogenesis" Unit at the Core Research Laboratory - Istituto Toscano Tumori, Careggi Hospital
- 10/2002 - 7/2007 Postdoctoral fellow at the Medical Research Council - Laboratory of Molecular Biology, Cambridge, UK (Dr. Michael Neuberger's Lab)
- 3/1999 - 8/2002 Postdoctoral fellow at the Weizmann Institute of Science, Rehovot, Israel (Dr. Mike Fainzilber's Lab)

Education

- 3/1998 - 12/1998 Visiting student at the Weizmann Institute of Science, Rehovot, Israel (Dr. Mike Fainzilber's Lab)
- 11/1995 - 3/1999 PhD program in "Medical Biology and Biochemistry". Institute of Biological Chemistry - University of Catania, Italy (Supervisors: Prof. D.F. Condorelli and Prof. R. Avola)
- 05/1996 Italian Medical license
- 07/1995 M.D. laude, Medical School - University of Catania, Italy (Thesis Supervisor: Prof. D.F. Condorelli)


Fellowships, Awards, Memberships, and Certifications

- 1995 "Prof. Ricceri" award for the M.D. degree thesis, Catania
- 1995 - 1999 PhD Fellowship , Catania – Bari
- 1997 - current Fellow of the Italian Society of Biochemistry and Molecular Biology (SIB)
- 1998 SIB Training and Research fellowship
- 2002 Zanichelli prize, 47° SIB meeting, Palermo
- 2002 FEBS long term fellowship (declined)
- 2002 - 2004 Marie Curie Postdoctoral fellowship
- 10/2012 - current Faculty of the PhD Programme in Genetics, Oncology e Clinical Medicine (GenOMeC), University of Siena
- 08/2018 – 09/2021 MC substitute for the European Epitranscriptomics Network – COST Action CA16120 EPITRAN
- 6/2023 - current Faculty of the PhD Programme in "RNA therapeutics and gene therapy", University of Napoli
- 2024 - current Founding member, Human RNome Project



Seminars, Courses, Invited Talks (past 5 years)

- 01/2020 Erasmus Course "Basic and Translational Oncology Course", Firenze
01/2020 1st International Conference on Base Editing (Deaminet 2020), Palm Springs
02/2020 Ospedale Pediatrico "Bambino Gesù", Roma
12/2020 2nd RNA Editing Summit (virtual meeting)
4-10/2021 "DNA/RNA editing: health, disease and biotechnological applications" Course, Scuola Superiore di Catania, academic year 2020-2021
01/2021 2nd International Conference on Base Editing – Enzymes and Applications (virtual meeting)
01/2022 3rd International Conference on Base Editing – Enzymes and Applications, Palm Springs
01/2022 University of South California
03/2022 Conferenza del CNR-DSB "Target discovery for unmet medical needs and precision/personalized medicine", Roma
06/2022 AID 2020+2, Quebec City
09/2022 Erasmus Course, Firenze
10/2023 University of Trieste
10/2023 ICGEB, Trieste
06/2024 48th FEBS Congress, Milano
10/2024 University of Trento
12/2024 Genome Editing and Stem Cell Reprogramming, Università Cattolica del Sacro Cuore
01/2022 6th International Conference on Base Editing – Enzymes and Applications, Palm Springs
02/2025 University of Siena
03/2025 Gordon Conference "RNA and DNA Editing and Modification", Barga (Lucca)
05/2025 IRST, Meldola
06/2025 IFO – Regina Elena, Roma

A handwritten signature in blue ink, appearing to read "S. Conticello".

Refereeing

Journals: Science; Cell; EMBO Journal; Journal of Biological Chemistry; Biochemical Journal; FEBS Letters; Proceedings of the Royal Society: Biological Sciences; Journal of General Virology; Evolution; WIREs RNA; ERMM; Molecular Biology and Evolution; Genome Biology; Nature Chemical Biology; PLoS One; Molecular and Cellular Proteomics; Journal of Molecular Biology; PLoS Genetics; Frontiers Immunology; Matters; Structure; Scientific Reports; Genome Research; Nucleic Acids Research; PNAS; Mutation Research; Science Advances; ACS Infectious Diseases; Nature Communications; Journal of Molecular Endocrinology; BMC Biology; Journal of Clinical Investigation; Journal of Immunology; Immunology; DNA Repair; European Journal of Human Genetics; Journal of Molecular Cell Biology; Molecular Therapy; NAR Cancer.

Editor: PLoS Genetics (guest editor), Frontiers in Genetics (associate editor)

Grant Agencies: National Science Foundation; AIDS Fonds Netherlands; Austrian Science Fund; United States-Israel Binational Science Foundation; Israel Science Foundation; European Research Council; Natural Sciences and Engineering Research Council of Canada; Cancer Research UK; Cancer Research UK; Cancer Research Trust – New Zealand; German-Israeli (DKFZ-MOST) cooperation in cancer research; Genesis Oncology Trust; Israel Science Foundation (ISF); The Paracelsus Medical University (PMU) Salzburg, Austria; COST; MSCA.

Organization of scientific meetings and events

- | | |
|-----------------|---|
| 1-3/7/2015 | 19th International Fritz-Bender Foundation Symposium , Pisa, Italy
https://www.unisi.it/unisilife/eventi/bender-symposium-itt-meeting |
| 12/6-10/10/2015 | Cancro: una sfida aperta (serie di seminari ed eventi divulgativi), Firenze
http://www.ittumori.it/IttSanitaSrtv/jsp/notizia.jsp?identif=11424 |
| 23/9/2016 | Organizzazione della sessione " Shaping the cancer genome: from pathways to mutational signatures " al Congresso FISV2016
http://fisv2016.azureon.org |
| 15-18/1/2018 | DNA and RNA editing by AID/APOBEC proteins , Ma'ale HaHamisha, Israel
https://rnaediting.wixsite.com/apobec-seminar |
| 29-30/3/2019 | COST Action CA16120 EPITRAN – " First EPITRAN Bioinformatic Workshop ", Firenze, Italy - https://epitran.eu |
| 20-22/9/2021 | COST Action CA16120 EPITRAN – " EPITRAN Final Conference ", online - https://epitran.eu |




- 2023-2025 "I seminari del VeRNAdi: A webinar series about RNA", Spoke 6, RNA drug development, National Center for Gene Therapy and Drugs based on RNA Technology, online
- 7/5/2025 4th Albrecht Müller Webinar, ARRIGE – ROPES – "Editing RNA or DNA: the great challenge", online - https://www.arrige.org/wp-content/uploads/2025/05/4AMA_summary.pdf

S. Conticello


List of Publications in international peer-reviewed journals (underlined if corresponding)

1. D.F. Condorelli, V.G. Nicoletti, V. Barresi, A. Caruso, **S. Conticello**, J. de Vellis, and A.M. Giuffrida Stella (1994). Tissue-specific DNA methylation patterns of the rat glial fibrillary acidic protein gene. *J Neurosci Res*, 39(6), 694-707.
2. D.F. Condorelli, P. Dell'Albani, **S.G. Conticello**, V. Barresi, V.G. Nicoletti, A. Caruso, M. Kahn, M. Vacanti, V. Albanese, J. de Vellis, and A.M. Giuffrida (1997). A neural-specific hypomethylated domain in the 5' flanking region of the glial fibrillary acidic protein gene. *Dev Neurosci*, 19(5), 446-56.
3. D.F. Condorelli, V.G. Nicoletti, V. Barresi, **S.G. Conticello**, A. Caruso, E.A. Tendi, and A.M. Giuffrida Stella (1999). Structural features of the rat GFAP gene and identification of a novel alternative transcript. *J Neurosci Res*, 56(3), 219-28.
4. D.F. Condorelli, V.G. Nicoletti, P. Dell'Albani, V. Barresi, A. Caruso, **S.G. Conticello**, N. Belluardo, and A.M. Giuffrida Stella (1999). GFAP β mRNA expression in the normal rat brain and after neuronal injury. *Neurochem Res*, 24(5), 709-14.
5. **S.G. Conticello**, Y. Pilpel, G. Glusman, and M. Fainzilber (2000). Position-specific codon conservation in hypervariable gene families. *Trends Genet*, 16(2), 57-9.
6. **S.G. Conticello**, Y. Gilad, N. Avidan, E. Ben-Asher, Z. Levy, and M. Fainzilber (2001). Mechanisms for evolving hypervariability: the case of conopeptides. *Mol Biol Evol*, 18(2), 120-31.
7. H. Jaaro, G. Beck, **S.G. Conticello**, and M. Fainzilber (2001). Evolving better brains: a need for neurotrophins? *Trends Neurosci*, 24(2), 79-85.
8. M. Tcherpakov, F.C. Bronfman, **S.G. Conticello**, A. Vaskovsky, Z. Levy, M. Niinobe, K. Yoshikawa, E. Arenas, and M. Fainzilber (2002). The p75 neurotrophin receptor interacts with multiple MAGE proteins. *J Biol Chem*, 277(51), 49101-4.
9. **S.G. Conticello**, N.D. Kowalsman, C. Jacobsen, G. Yudkovsky, K. Sato, Z. Elazar, C.M. Petersen, A. Aronheim, and M. Fainzilber (2003). The prodomain of a secreted hydrophobic mini-protein facilitates its export from the endoplasmic reticulum by hitchhiking on sorting receptors. *J Biol Chem*, 278(29), 26311-4.
10. **S.G. Conticello**, R.S. Harris, and M.S. Neuberger (2003). The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. *Curr Biol*, 13(22), 2009-13.
11. **S.G. Conticello**, C.J. Thomas, S.K. Petersen-Mahrt, and M.S. Neuberger (2005). Evolution of the AID/APOBEC Family of Polynucleotide (Deoxy)cytidine Deaminases. *Mol Biol Evol*, 22(2), 367-77.
12. M.A. Langlois, R.C. Beale, **S.G. Conticello**, and M.S. Neuberger (2005). Mutational comparison of the single-domain APOBEC3C and double-domain APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. *Nucleic Acids Res*, 33(6), 1913-1923.

13. **S.G. Conticello**, M.A. Langlois, and M.S. Neuberger (2007). Insights into DNA deaminases. *Nat Struct Mol Biol*, 14(1), 7-9.
14. **S.G. Conticello**, M.A. Langlois, Z. Yang, and M.S. Neuberger (2007). DNA deamination in immunity: AID in the context of its APOBEC relatives. *Advances in Immunology*, 94, 37-73.
15. **S.G. Conticello** (2008). The AID/APOBECs, a family of nucleic acid mutators. *Genome Biol*. 9:6, 229.
16. **S.G. Conticello**, K. Ganesh, K. Xue, M. Lu, C. Rada, and M.S. Neuberger (2008). Interaction between antibody-diversification enzyme AID and spliceosome-associated factor CTNNBL1. *Mol Cell*, 31:4, 474-84.
17. R.S. LaRue, V. Andrésdóttir, Y. Blanchard, **S.G. Conticello**, D. Derse, M. Emerman, W.C. Greene, S.R. Jónsson, N.R. Landau, M. Löchelt, H.S. Malik, M.H. Malim, C. Münk, S.J. O'Brien, V.K. Pathak, K. Strelbel, S. Wain-Hobson, X.F. Yu, N. Yuhki and R.S. Harris (2009). Guidelines for naming nonprimate APOBEC3 genes and proteins. *J Virol* 83:2, 494-7.
18. F. Severi, A. Chicca, and **S.G. Conticello** (2011). Analysis of reptilian APOBEC1 suggests that RNA editing may not be its ancestral function. *Mol Biol Evol*, 28(3):1125–1129.
19. A. Orthwein A., Zahn A., S.P. Methot, D. Godin, **S.G. Conticello**, K. Terada, and J.M. Di Noia (2011). Optimal functional levels of activation-induced deaminase specifically require the Hsp40 DnaJa1. *EMBO J*. 31(3):679-91.
20. **S.G. Conticello** (2012). Creative deaminases, self-inflicted damage, and genome evolution. *Ann N Y Acad Sci*. 1267(1):79-85.
21. G. Saraconi*, F. Severi*, C. Sala, G. Mattiuz, **S.G. Conticello** (2014). The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas. *Genome Biol*. 15(7):417.
22. F. Severi, **S.G. Conticello** (2015). Flow-cytometric visualization of C>U mRNA editing reveals the dynamics of the process in live cells. *RNA Biol* 12(4):389-97.
23. C. Sala, G. Mattiuz, S. Pietrobono, A. Chicca, **S.G. Conticello** (2015). Splice variants of activation induced deaminase (AID) do not affect the efficiency of class switch recombination in murine CH12F3 cells. *PLoS One* 10(3):e0121719
24. **S.G. Conticello**, C. Rada (2016). Harnessing mutation: The best of two worlds. *Science* 353:6305, 1206-7. doi: 10.1126/science.aai8233
25. F. Niccheri, R. Pecori, **S.G. Conticello** (2017). An efficient method to enrich for knock-out and knock-in cellular clones using the CRISPR/Cas9 system. *Cell Mol Life Sci* 74(18):3413-3423. Doi: 10.1007/s00018-017-2524-y
26. A. St Martin, D. Salamango, A. Serebrenik, N. Shaban, W.L. Brown, F. Donati, U. Munagala, **S.G. Conticello**, R.S. Harris (2018). A fluorescent reporter for quantification and enrichment of DNA editing by APOBEC-Cas9 or cleavage by Cas9 in living cells. *Nucleic Acids Res*. 46(14):e84. doi: 10.1093/nar/gky332.




27. Petersen-Mahrt S., **Conticello S.**, and Munagala U. (2018). Activation-Induced Deaminase. eLS 1-12. doi: 10.1002/9780470015902.a0024241
28. Daga S., Donati F., Capitani K., Croci S., Tita R., Giliberti A., Valentino F., Benetti E., Fallarini C., Niccheri F., Baldassarri M., Mencarelli M. A., Frullanti E., Furini S., **Conticello S. G.**, Renieri A., Pinto A. M. (2019). New frontiers to cure Alport syndrome: COL4A3 and COL4A5 gene editing in podocyte-lineage cells : COL4A3 and COL4A5 gene editing in Alport syndrome. *Eur J Hum Genet*. doi: 10.1038/s41431-019-0537-8
29. Croci S., Carriero M. L., Capitani K., Daga S., Donati F., Frullanti E., Lamacchia V., Tita R., Giliberti A., Valentino F., Benetti E., Ciabattini A., Furini S., Lo Rizzo C., Pinto A. M., **Conticello S. G.**, Renieri A., Meloni I. (2020). High rate of HDR in gene editing of p.(Thr158Met) MECP2 mutational hotspot. *Eur J Hum Genet*. doi: 10.1038/s41431-020-0624-x
30. Di Giorgio S., Martignano F., Torcia M. G., Mattiuz G., **Conticello S. G.** (2020). Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2. *Science Advances*. doi: 10.1126/sciadv.abb5813
31. Croci S., Carriero M. L., Capitani K., Daga S., Donati F., Papa F. T., Frullanti E., Lopergolo D., Lamacchia V., Tita R., Giliberti A., Benetti E., Niccheri F., Furini S., Lo Rizzo C., **Conticello S. G.**, Renieri A., and Meloni I. (2020). AAV-mediated FOXG1 gene editing in human Rett primary cells. *Eur J Hum Genet* doi: 10.1038/s41431-020-0652-6
32. Destefanis E., Avşar G., Groza P., Romitelli A., Torrini S., Pir P., **Conticello S. G.**, Aguiló F., and Dassi E. (2020). A mark of disease: how mRNA modifications shape genetic and acquired pathologies. *RNA* doi: 10.1261/ma.077271.120
33. Martignano F., Munagala U., Crucitta S., Mingrino A., Semeraro R., Del Re M., Petrini I., Magi A., **Conticello S.G.** (2021) Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients. *Molecular Cancer* 20(1):32. doi: 10.1186/s12943-021-01327-5
34. Rogier M., Moritz J., Robert I., Lescale C., Heyer V., Abello A., Martin O., Capitani K., Thomas M., Thomas-Claudepierre A.S., Laffleur B., Jouan F., Pinaud E., Tarte K., Cogné M., **Conticello S.G.**, Soutoglou E., Deriano L., Reina-San-Martin B. (2021). Fam72a enforces error-prone DNA repair during antibody diversification. *Nature* 600(7888):329-333. doi: 10.1038/s41586-021-04093-y
35. Boccaletto P., Stefaniak F., Ray A., Cappannini A., Mukherjee S., Purta E., Kurkowska M., Shirvanizadeh N., Destefanis E., Groza P., Avşar G., Romitelli A., Pir P., Dassi E., **Conticello S.G.**, Aguiló F., Bujnicki J.M. (2022). MODOMICS: a database of RNA modification pathways. 2021 update. *Nucleic Acids Res.* 50(D1):D231-D235. doi: 10.1093/nar/gkab1083
36. Polvani S.; Martignano F., Scoccianti G., Pasqui A., Palomba Anna R., **Conticello S.G.**, Galli A., Palchetti I., Caporali C., Antonuzzo L., Campanacci Domenico A., Pillozzi S. (2022). Growth arrest-specific 5 lncRNA as a valuable biomarker of chemoresistance in osteosarcoma. *Anti-*



- cancer drugs 33(3) 278-285. doi: 10.1097/CAD.0000000000001263
37. Martignano F., Di Giorgio S., Mattiuz G., **Conticello S.G.** (2022). Commentary on "Poor evidence for host-dependent regular RNA editing in the transcriptome of SARS-CoV-2". *J Appl Genet.* 63(2):423-428. doi: 10.1007/s13353-022-00688-x
38. Katsman E.*, Orlanski S. *, Martignano F. *, Fox-Fisher I., Shemer R., Dor Y., Zick A., Eden A., Petrini I., **Conticello S.G***, Berman B.P. * (2022). Detecting cell-of-origin and cancer-specific methylation features of cell-free DNA from Nanopore sequencing. *Genome Biology.* 23(1):158. doi: 10.1186/s13059-022-02710-1
39. Cosi I., Moccia A., Pescucci C. , Munagala U., Di Giorgio S., Sineo I., **Conticello S.G.**, Notaro R., De Angioletti M. (2023). Identification and characterization of novel ETV4 splice variants in prostate cancer. *Scientific Reports* 13(1):5267. doi: 10.1038/s41598-023-29484-1
40. Naumann J.A., Argyris P.P., Carpenter M.A., Gupta H.B., Chen Y., Temiz N.A., Zhou Y., Durfee C., Proehl J., Koniar B.L., **Conticello S.G.**, Largaespada D.A., Brown W.L., Aihara H., Vogel R.I., Harris R.S. (2023). DNA Deamination Is Required for Human APOBEC3A-Driven Hepatocellular Carcinoma In Vivo. *Int J Mol Sci.* 24(11):9305. doi: 10.3390/ijms24119305.
41. Biancolella M., Colona V.L., Luzzatto L., Watt J.L., Mattiuz G., **Conticello S.G.**, Kaminski N., Mehrian-Shai R., Ko A.I., Gonsalves G.S., Vasiliou V., Novelli G., Reichardt J.K.V. (2023). COVID-19 annual update: a narrative review. *Hum Genomics.* 17(1):68. doi: 10.1186/s40246-023-00515-2.
42. De Paolo R., Munagala U., Cucco F., Sarti S., Pitto L., Martignano F., **Conticello S.G.**, Poliseno L. (2023). Modified Cas9-Guided Oxford Nanopore Technology Sequencing Uncovers Single and Multiple Transgene Insertion Sites in a Zebrafish Melanoma Model. *CRISPR J.* 6(6):489-492. doi: 10.1089/crispr.2023.0062.
43. Fonzino A., Manzari C., Spadavecchia P., Munagala U., Torrini S., **Conticello S.**, Pesole G., Picardi E. (2024). Unraveling C-to-U RNA editing events from direct RNA sequencing. *RNA Biol.* 21(1):1-14. doi: 10.1080/15476286.2023.2290843.
44. Mattiuz G., Di Giorgio S., **Conticello S.G.**, Pesole G., Picardi E. (2024). An elusive debate on the evidence for RNA editing in SARS-CoV-2. *RNA Biol.* 21(1): 1. doi: 10.1080/15476286.2024.2321032.
45. Wallach, I. et al. (2024). AI is a viable alternative to high throughput screening: a 318-target study. *Sci. Rep.* 14, 7526 (2024). doi: 10.1038/s41598-024-54655-z

Book Chapters

1. Chieca M., Torrini S., and **Conticello S. G.** (2021). Live-Cell Quantification of APOBEC1-Mediated RNA Editing: A Comparison of RNA Editing Assays. *Methods Mol Biol* 2181, 69-81. doi: 10.1007/978-1-0716-0787-9_5



Other Publications

1. **Conticello, S.** (2018). Scientists informing policy should disclose their own beliefs. *Nature* 560(7719), 431. doi: 10.1038/d41586-018-06017-9
2. **Conticello, S.** (2021). Open access: pay- for-review option — ethical questions. *Nature* 590(7844):36. doi: 10.1038/d41586-021-00271-0

Manuscripts in Preprint Repositories

1. G. Mattiuz, S. Di Giorgio, L. Tofani, A. Frandi, F. Donati, M. Brilli, **S.G. Conticello** (2018) Mutational likeliness and entropy help to identify driver mutations and their functional role in cancer. BioRxiv doi: 10.1101/354324
2. M. Chieca, M.D. Montini, F. Severi, R. Pecori, **S.G. Conticello** (2018). Dimerisation of APOBEC1 is dispensable for its RNA editing activity. BioRxiv doi: 10.1101/410803

Patents

1. 2019 - Donati F., Niccheri F., Renieri A., Papa F., **Conticello S.**, Lorenzetti F., Mari F. - CRISPR/Cpf1 as a tool for locus specific delivery of suicide gene in cancers. Sistema CRISPR-Cas per l'editing genomico, brevetto n. 102018000009431 (granted in Italy), 2020/079574 A1 (international) WIPO (PCT) WO2020079574A9
2. 2019 - **Conticello S.**, Daga S., Lopergolo D., Donati F., Croci S., Renieri A., Pinto A., Meloni I. - CRISPR/Cas9 as a tool for therapeutic intervention in Alport Syndrome, Pompe disease, Rett Syndrome, and Parkinson Disease. brevetto n. 102018000020230 (granted in Italy), IT201800020230A1)
3. 2020 - **Conticello S.**, Severi F., Donati F. (2020). Cytidine deaminase variants for base editing. 102020000028688, Consiglio Nazionale delle Ricerche), WIPO (PCT) WO2022112404A1 (granted)
4. 2021 - Berman B., Katsman E., Orlanski S., **Conticello S.**, Martignano F. (2021). Use of Nanopore sequencing for determining the origin of circulating DNA. WIPO (PCT) WO2023067597A1 63256655 (USA) (pending)

Plasmidic vectors deposited in Addgene

1. pBS SK mCherryROSAbsr (Addgene # 54321)
2. pBS SK mCherryROSAegfp (Addgene # 54322)
3. pCAGGS-ROSAf (Addgene # 54323)
4. pCAGGS-ROSAr (Addgene # 54324)
5. pBSR (mCherry-surrogateTarget-bsr) (Addgene # 66950)
6. EGFP-rat APOBEC1 (Addgene # 112856)
7. rat APOBEC1-EGFP (Addgene # 112857)

8. rat APOBEC1 (Addgene # 112858)
9. pEGFP mCherry-ApoB-EGFP (Addgene # 112859)
10. human ACF (Addgene # 112860)
11. rat APOBEC1 E63A (Addgene # 112861)
12. pEGFP-N1-mCherry-ApoB-TagBFP (Addgene # 129383)
13. pAAV_Donor/Reporter-COL4A3 (Addgene # 130279)
14. pAAV_Donor/Reporter-COL4A5 (Addgene # 130280)
15. pAAV_COL4A3_self-cleavingCas9 (Addgene # 130281)
16. pAAV_COL4A5_self-cleavingCas9 (Addgene # 130282)
17. pBlueScript-humanAPOBEC1 (Addgene # 134606)
18. pEGFP-N1-Flag-humanRBM47 (Addgene # 134607)

(*) ai sensi dell'art. 15, comma 1 della Legge 12/11/2011, n. 183 le certificazioni rilasciate dalla P.A. in ordine a stati, qualità personali e fatti sono valide e utilizzabili solo nei rapporti tra privati; nei rapporti con gli Organi della Pubblica Amministrazione e i gestori di pubblici servizi, i certificati sono sempre sostituiti dalle dichiarazioni sostitutive di certificazione o dall'atto di notorietà di cui agli artt. 46 e 47 del DPR 445/2000

The undersigned, aware of the penalties provided for by the penal code, and by special laws against anyone who issues false declarations, also aware of the possibility of losing the benefits resulting from any provisions issued on the basis of untruthful declaration, declares that everything stated in the curriculum vitae corresponds to truth - art. 46, D.P.R. 445/2000.

